Immunonutrition in the perioperative period of ovarian cancer: from molecular mechanism to clinical application

Ovarian cancer is a major disease that poses a serious threat to the life and health of women worldwide, exhibiting the highest mortality rate among all gynaecological tumours. Patients with ovarian cancer often experience malnutrition due to factors such as tumour-related nutritional depletion and stress responses resulting from surgery. This malnutrition status in turn increases complications, mortality, and economic burden; affects treatment efficacy and prognosis; and prolongs hospitalisation time. Therefore, patients with ovarian cancer should be monitored for malnutrition and provided with prompt, adequate nutritional support in addition to surgery. Arginine, glutamine, omega-3 polyunsaturated fatty acids, probiotics, and multiple vitamins are the most widely studied immunonutrients. Moreover, patients with ovarian cancer require individualised nutritional support, with enteral and parenteral nutrition being the presently employed primary methods of nutritional support.

Ovarian cancer; Immunonutrition; Pathogenesis; Support pathways; Nutrients

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a Cancer Journal for Clinicians. 2023; 73: 17–48.

[2] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a Cancer Journal for Clinicians. 2022; 72: 7–33.

[3] Alghamdi N, Chang W, Dang P, Lu X, Wan C, Gampala S, et al. A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data. Genome Research. 2021; 31: 1867–1884.

[4] Purohit V, Wagner A, Yosef N, Kuchroo VK. Systems-based approaches to study immunometabolism. Cellular & Molecular Immunology. 2022; 19: 409–420.

[5] Wu Q, Liu Z, Li B, Liu YE, Wang P. Immunoregulation in cancer-associated cachexia. Journal of Advanced Research. 2024; 58: 45–62.

[6] Sowerbutts AM, Lal S, Sremanakova J, Clamp AR, Jayson GC, Teubner A, et al. Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers. BMC Palliative Care. 2019; 18: 120.

[7] Noba L, Wakefield A. Are carbohydrate drinks more effective than preoperative fasting: a systematic review of randomised controlled trials. Journal of Clinical Nursing. 2019; 28: 3096–3116.

[8] Cho E, Lee NH, Ahn J, Choi W, Byun J, Song T. Preoperative oral carbohydrate loading in laparoscopic gynecologic surgery: a randomized controlled trial. Journal of Minimally Invasive Gynecology. 2021; 28: 1086–1094.e1.

[9] Schilder JM, Hurteau JA, Look KY, Moore DH, Raff G, Stehman FB, et al. A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery. Gynecologic Oncology. 1997; 67: 235–240.

[10] Braga M, Vignali A, Gianotti L, Cestari A, Profili M, Di Carlo V. Benefits of early postoperative enteral feeding in cancer patients. Transfusion Medicine and Hemotherapy. 1995; 22: 280–284.

[11] Davoudi M, Jadidi Y, Moayedi K, Farrokhi V, Afrisham R. Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011-2022 review. Journal of Nanobiotechnology. 2022; 20: 504.

[12] Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clinical nutrition. 2021; 40: 2898–2913.

[13] Sindhu R, Supreeth M, Prasad SK, Thanmaya M. Shuttle between arginine and lysine: influence on cancer immunonutrition. Amino Acids. 2023; 55: 1461–1473.

[14] Paßlack N, Doherr MG, Zentek J. Effects of free amino acids on cytokine secretion and proliferative activity of feline T cells in an in vitro study using the cell line MYA-1. Cytotechnology. 2016; 68: 1949–1961.

[15] Kang K, Shu XL, Zhong JX, Yu TT. Effect of L-arginine on immune function: a meta-analysis. Asia Pacific Journal of Clinical Nutrition. 2014; 23: 351–359.

[16] Sittitrai P, Ruenmarkkaew D, Booyaprapa S, Kasempitakpong B. Effect of a perioperative immune-enhancing diet in clean-contaminated head and neck cancer surgery: a randomized controlled trial. International Journal of Surgery. 2021; 93: 106051.

[17] Albaugh VL, Pinzon-Guzman C, Barbul A. Arginine-Dual roles as an onconutrient and immunonutrient. Journal of Surgical Oncology. 2017; 115: 273–280.

[18] Park KG, Heys SD, Blessing K, Kelly P, McNurlan MA, Eremin O, et al. Stimulation of human breast cancers by dietary L-arginine. Clinical Science. 1992; 82: 413–417.

[19] Nazarian B, Fazeli Moghadam E, Asbaghi O, Zeinali Khosroshahi M, Choghakhori R, Abbasnezhad A. Effect of l-arginine supplementation on C-reactive protein and other inflammatory biomarkers: a systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. 2019; 47: 102226.

[20] Li T, Copeland C, Le A. Glutamine metabolism in cancer. Advances in Experimental Medicine and Biology. 2021; 1311: 17–38.

[21] Wang J, Wang N, Qi M, Li J, Tan B. Glutamine, glutamate, and aspartate differently modulate energy homeostasis of small intestine under normal or low energy status in piglets. Animal Nutrition. 2022; 8: 216–226.

[22] Fasoulakis Z, Koutras A, Ntounis T, Prokopakis I, Perros P, Chionis A, et al. Ovarian cancer and glutamine metabolism. International journal of Molecular Sciences. 2023; 24: 5041.

[23] Kuroki K, Rikimaru F, Kunitake N, Toh S, Higaki Y, Masuda M. Efficacy of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine for the prevention of mucositis induced by platinum-based chemoradiation in head and neck cancer: a phase II study. Clinical Nutrition ESPEN. 2023; 57: 730–734.

[24] Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Research. 2020; 80: 4514–4526.

[25] Anderson PM, Lalla RV. Glutamine for amelioration of radiation and chemotherapy associated mucositis during cancer therapy. Nutrients. 2020; 12: 1675.

[26] Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Annals of Pharmacotherapy. 2008; 42: 1481–1485.

[27] Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clinical Oncology. 2005; 17: 271–276.

[28] Loven D, Levavi H, Sabach G, Zart R, Andras M, Fishman A, et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. European Journal of Cancer Care. 2009; 18: 78–83.

[29] Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 2014; 10: 728.

[30] Pal P, Hales K, Petrik J, Hales DB. Pro-apoptotic and anti-angiogenic actions of 2-methoxyestradiol and docosahexaenoic acid, the biologically derived active compounds from flaxseed diet, in preventing ovarian cancer. Journal of Ovarian Research. 2019; 12: 49.

[31] Wang Y, Liu K, Long T, Long J, Li Y, Li J, et al. Dietary fish and omega-3 polyunsaturated fatty acids intake and cancer survival: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. 2023; 63: 6235–6251.

[32] Zajdel A, Kałucka M, Chodurek E, Wilczok A. DHA but not AA enhances cisplatin cytotoxicity in ovarian cancer cells. Nutrition and Cancer. 2018; 70: 1118–1125.

[33] Zhao Y, Zhao MF, Yang ML, Wu TY, Xu CJ, Wang JM, et al. G protein-coupled receptor 30 mediates the anticancer effects induced by eicosapentaenoic acid in ovarian cancer cells. Cancer Research and Treatment. 2020; 52: 815–829.

[34] Wan XH, Fu X, Ababaikeli G. Docosahexaenoic acid induces growth suppression on epithelial ovarian cancer cells more effectively than eicosapentaenoic acid. Nutrition and Cancer. 2016; 68: 320–327.

[35] Eilati E, Bahr JM, Hales DB. Long term consumption of flaxseed enriched diet decreased ovarian cancer incidence and prostaglandin E₂in hens. Gynecologic Oncology. 2013; 130: 620–628.

[36] Dikshit A, Hales K, Hales DB. Whole flaxseed diet alters estrogen metabolism to promote 2-methoxtestradiol-induced apoptosis in hen ovarian cancer. The Journal of Nutritional Biochemistry. 2017; 42: 117–125.

[37] Chase D, Goulder A, Zenhausern F, Monk B, Herbst-Kralovetz M. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. Gynecologic Oncology. 2015; 138: 190–200.

[38] Sipos A, Ujlaki G, Mikó E, Maka E, Szabó J, Uray K, et al. The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Molecular Medicine. 2021; 27: 33.

[39] Visich KL, Yeo TP. The prophylactic use of probiotics in the prevention of radiation therapy-induced diarrhea. Clinical Journal of Oncology Nursing. 2010; 14: 467–473.

[40] Lokman NA, Ho R, Gunasegaran K, Bonner WM, Oehler MK, Ricciardelli C. Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. Journal of Experimental & Clinical Cancer Research. 2019; 38: 10.

[41] Wang Q, He C. Dietary vitamin A intake and the risk of ovarian cancer: a meta-analysis. Bioscience Reports. 2020; 40: BSR20193979.

[42] Takahashi N. Inhibitory effects of Vitamin A and its derivatives on cancer cell growth not mediated by retinoic acid receptors. Biological & Pharmaceutical Bulletin. 2022; 45: 1213–1224.

[43] Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Reviews. 2015; 34: 41–52.

[44] Arthur RS, Kirsh VA, Rohan TE. Dietary B-Vitamin intake and risk of breast, endometrial, ovarian and colorectal cancer among Canadians. Nutrition and Cancer. 2019; 71: 1067–1077.

[45] Wang K, Zhang Q, Yang J. The effect of folate intake on ovarian cancer risk: a meta-analysis of observational studies. Medicine. 2021; 100: e22605.

[46] Kim JE, Cho HS, Yang HS, Jung DJ, Hong SW, Hung CF, et al. Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model. Immunobiology. 2012; 217: 873–881.

[47] Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science Translational Medicine. 2014; 6: 222ra18.

[48] Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. Journal of the American College of Nutrition. 2003; 22: 118–123.

[49] Kitami K, Yoshihara M, Tamauchi S, Sugiyama M, Koya Y, Yamakita Y, et al. Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-β1/thrombospondin-1 axis. Matrix Biology. 2022; 109: 70–90.

[50] Ji J, Cheng X, Wang W, Zhang J. Vitamin D regulates cell viability, migration and proliferation by suppressing galectin-3 (Gal-3) gene in ovarian cancer cells. Journal of Biosciences. 2020; 45: 69.

[51] Wang L, Zhou S, Guo B. Vitamin D suppresses ovarian cancer growth and invasion by targeting long non-coding RNA CCAT2. International Journal of Molecular Sciences. 2020; 21: 2334.

[52] Constantinou C, Charalambous C, Kanakis D. Vitamin E and cancer: an update on the emerging role of γ and δ tocotrienols. European Journal of Nutrition. 2020; 59: 845–857.

[53] Fontana F, Marzagalli M, Raimondi M, Zuco V, Zaffaroni N, Limonta P. δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis. Cell Proliferation. 2021; 54: e13111.

[54] Thomsen CB, Andersen RF, Steffensen KD, Adimi P, Jakobsen A. Delta tocotrienol in recurrent ovarian cancer. A phase II trial. Pharmacological Research. 2019; 141: 392–396.

[55] Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005; 64: 26–31.

[56] Markowska A, Antoszczak M, Markowska J, Huczyński A. Role of Vitamin E in selected malignant neoplasms in women. Nutrition and Cancer. 2022; 74: 1163–1170.

[57] Leng Y, Zhou H, Meng F, Tian T, Xu J, Yan F. Association of vitamin E on the risk of ovarian cancer: a meta-analysis. Bioscience Reports. 2019; 39: BSR20193311.

[58] Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hajek RA, Handy B, et al. A randomized parallel-group dietary study for stages II–IV ovarian cancer survivors. Gynecologic Oncology. 2012; 124: 410–416.

[59] El-Sherif A, El-Sherif S, Taylor AH, Ayakannu T. Ovarian cancer: lifestyle, diet and nutrition. Nutrition and Cancer. 2017; 73: 1092–1107.

[60] Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN practical guideline: clinical nutrition in surgery. Clinical Nutrition. 2021; 40: 4745–4761.

[61] Chapman JS, Roddy E, Westhoff G, Simons E, Brooks R, Ueda S, et al. Post-operative enteral immunonutrition for gynecologic oncology patients undergoing laparotomy decreases wound complications. Gynecologic Oncology. 2015; 137: 523–528.

[62] Buzquurz F, Bojesen RD, Grube C, Madsen MT, Gögenur I. Impact of oral preoperative and perioperative immunonutrition on postoperative infection and mortality in patients undergoing cancer surgery: systematic review and meta-analysis with trial sequential analysis. BJS Open. 2020; 4: 764–775.

[63] Martínez-Ortega AJ, Piñar-Gutiérrez A, Serrano-Aguayo P, González-Navarro I, Remón-Ruíz PJ, Pereira-Cunill JL, et al. Perioperative nutritional support: a review of current literature. Nutrients. 2022; 14: 1601.

[64] Heidegger CP, Darmon P, Pichard C. Enteral vs. parenteral nutrition for the critically ill patient: a combined support should be preferred. Current Opinion in Critical Care. 2008; 14: 408–414.

[65] Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Goldstein BH. The impact of total parenteral nutrition on postoperative recovery in patients treated for advanced stage ovarian cancer. Archives of Gynecology and Obstetrics. 2017; 295: 439–444.

[66] Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, et al. ESPEN practical guideline: home parenteral nutrition. Clinical Nutrition. 2023; 42: 411–430.

[67] Vashi PG, Dahlk S, Popiel B, Lammersfeld CA, Ireton-Jones C, Gupta D. A longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition. BMC Cancer. 2014; 14: 593.